Active Ingredient: | Fenbendazole |
---|---|
Indication: | Treat a Variety of Parasites |
Manufacturer: | Actiza Pharmaceutical Pvt. Ltd. |
Packaging: | 10 tablet in 1 strip |
Strength: | 1000mg |
Delivery Time: | 6 To 15 days |
Fenbendazole 1000 mg Tablet (Wormiza)
1000mg | Price | Price/unit | Qty | Cart |
---|---|---|---|---|
100 Tablet/s | AUD$93.60 | AUD$0.94/Tablet | ||
200 Tablet/s | AUD$168.48 | AUD$0.84/Tablet | ||
300 Tablet/s | AUD$226.20 | AUD$0.75/Tablet |
Fenbendazole 1000 mg is a broad-spectrum benzimidazole compound that has been widely used as a veterinary anthelmintic drug intended specifically to treat gastrointestinal parasites in animals. In the last few years, Fenbendazole has been repurposed off-label, investigationally in humans. Experimental uses in parasitic infections have occurred and more recently, there have even been a few suggested applications for possible involvement in integrative care in cancer therapy. The rise of popularity for fenbendazole comes from anecdotal reports, and there is emerging preclinical evidence that Fenbendazole may inhibit the process of microtubule formation in cancer cells, similar to chemotherapy.
Even though veterinary grade Fenbendazole has not been approved for use by humans by any regulatory body, such as the FDA, individuals acting on their own or in conjunction with an alternative health practitioner have taken veterinary grade Fenbendazole under their personal prerogative. It should be noted that there is nothing particularly concerning about taking off-label medications, but care must always be taken. Clinical evidence is sparse, and under proper medical supervision. There is great potential for Fenbendazole to be effective in certain cancer indications. Caution should be used with its use, particularly as with most medications that cross over from veterinary to human.
Fenbendazole represents a benzimidazole class of antiparasitic drugs. It pharmacologically acts as it binds to β-tubulin, which is a structural protein that is required by cells for microtubule assembly. Disruption of the cell's cytoskeleton, particularly in fast-dividing parasitic cells, is detrimental enough to disrupt glucose uptake, deplete energy, and induce cell death.
For humans, that same disruption has raised an appeal for anti-cancer efficacy as malignant cells, optimal for rapid mitosis, have a state they adhere to regarding the structural integrity of microtubules. If fenbendazole targets tubulin and interferes with the ability of malignant cells to enter into mitosis and induce apoptosis while causing considerably less harm to normal cells, based on preclinical studies, we have reason to investigate its potential further.
Fenbendazole's low absorptive capacity in the GI tract could prove advantageous as it targets parasites of the digestive tract, but low systemic exposure could be further countered if fenbendazole is taken with a fatty meal. Fenbendazole might be metabolized primarily by the liver to active sulfoxide and sulfone metabolites that also provide fenbendazole with an extensive period of antiparasitic activity, and potentially provide additional use as a pan therapeutic resource for humans pending clinical studies.
Fenbendazole is licensed for use in veterinary medicine and is used in a number of animal species to treat parasitic infections. Fenbendazole can be used against many gastrointestinal parasites as it is active against a large range of nematodes, especially roundworms, hookworms, whipworms, strongyles, and some species of tapeworms.
Fenbendazole is routinely used in dogs for Giardia, Toxocara canis, and Ancylostoma caninum. While in cats, it may be used off-label for similar purposes. For food animals like cattle, sheep, and goats, fenbendazole is a dewormer that can effectively act against Haemonchus, Ostertagia, and Trichostrongylus species.
Horses are commonly treated with fenbendazole to eliminate strongyles and pinworms. Poultry, pigs, and even reptiles, and other exotic species, are being treated with fenbendazole under veterinary supervision.
Fenbendazole is typically given orally, in paste, granules, or suspension. The dosage of fenbendazole differs by species and body weight. Due to the large safety margin in most animals, fenbendazole is an attractive option for regular and preventative deworming, but concerns for resistance have become monitored more frequently over the years, especially in developed regions, and in large-scale farming.
When using Wormiza 222 mg, Fenbendazole 150 mg tablets, or Fenbendazole 1000 mg, adherence to stringent dosing guidelines is paramount. The active ingredient Fenbendazole, is a veterinary anti-parasitic that is used off-label in humans for parasitic infections, potential therapy for autism and cancer, and other investigational therapies. The dosage that is routinely discussed for humans is 150 mg-222 mg daily for 3 days, then rest for 4 days, and the cycle is repeated weekly. Since the only intact product available in Canada is the 1000 mg formulation, it is broken down into smaller doses to get into the appropriate therapeutic range for humans.
When taking the tablets, take them with a fatty meal to increase absorption. Please do not exceed the recommended dosages without medical supervision. The tablets should be swallowed whole with water and should not be crushed unless instructed. Maintaining consistent dosing is important so that you maintain therapeutic levels in the system.
Please see a healthcare provider before consumption, particularly if pregnant, breastfeeding, or taking other medications. Despite the potential for human use, the use of Fenbendazole products, like Wormiza 222 mg, should be approached cautiously due to a lack of clinical data.
Fenbendazole is thought to have a good safety profile when used as directed, for both veterinary and human off-label use. In the cases of anecdotal human usage, the reported dosages have generally been considered low, and with almost no side effects. That said, we should point out that some veterinary Fenbendazole formulations have additives that are either not appropriate for human use or for consumption.
Regarding human users, reported side effects were generally mild, including nausea, bloating, headache, or an elevation in liver enzymes, and rare cases, allergy or gastrointestinal upset. There is little to no long-term safety evidence in humans.
Fenbendazole has also been used in animals and has a very good safety record, including in pregnant or lactating animals without incident. Indeed, overdosing on Fenbendazole can cause vomiting, diarrhea, and lethargy, however.
With the mechanism of action of targeting microtubules, there remains a concern about long-term use in humans, especially under a situation where no medical supervision is being offered, as it affects cellular processes in normal cells. This concern would be especially relevant to rapidly dividing cells such as those in the bone marrow. During likely periods of exposure, regular blood counts and/or liver function should be monitored.
Fenbendazole is not FDA approved for human use and anyone who considers it should do so with great caution. Its off-label use is experimental, and should be considered a trial, under the supervision of an appropriately qualified healthcare professional, especially in respect to the treatment of cancer or chronic illness.
Those with liver disease should be even more cautious, as Fenbendazole is metabolized by the liver and could raise liver enzymes. Professional medical advice and frequent liver function tests should be recommended if long-term use is planned. Suspected hypersensitivity to benzimidazoles should include complete avoidance of the drug.
Pregnant or breastfeeding women are advised against using Fenbendazole due to unknown risks to the development of a fetus or infant. Further, using Fenbendazole with other hepatotoxic drugs or chemotherapeutic agents could potentially put patients at increased risk of liver toxicity, as well as any unexpected interactions.
Veterinary use formulations may contain inactive excipients that could not be tested for human safety. If used under the precautions mentioned here, only pharmaceutical grade or compounds verified for safety should be considered.
As with all off-label drugs, the use of Fenbendazole in humans should be considered only after weighing the risks and benefits with a medical professional.
It is not FDA-approved for humans, but some individuals use it off-label under medical supervision. Safety is not fully established.
Common anecdotal protocols suggest 222mg daily for 3–5 days per week, but this is not officially validated. Always consult a healthcare provider.
Long-term safety in humans is unknown. Liver monitoring is advised if taken for extended periods.
Yes, taking it with fatty meals may improve absorption and bioavailability.
Dominic Holmwood
July 28, 2025Good for long-term infection control in humans.
Reply